BioSpace News Archive

Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard of care chemotherapy in the primary trial population of patients with HR positive, HER2 low metastatic breast cancer following one or more lines of endocrine therapy.

Foresee Pharmaceuticals announced that it will actively participate in and present two posters at the 2024 American Thoracic Society International Conference, which will be held in San Diego, CA, from May 17 to 22, 2024.

Immunovia AB announced that the Annual Report for 2023 has been published.

MiLaboratories, a leader in RNA immune technologies, and Miltenyi Biotec, a global pioneer in biotechnology, are excited to announce a landmark partnership that promises to revolutionize the field of next-generation therapies.

Coave Therapeutics announces that preclinical studies on its novel Conjugated AAV gene therapy vectors demonstrate promising results for ocular gene therapy.

X4 Pharmaceuticals, a company driven to improve the lives of people with rare diseases of the immune system, announced that the U.S. Food and Drug Administration has approved XOLREMDI™ capsules for use in patients 12 years of age and older with WHIM syndrome to increase the number of circulating mature neutrophils and lymphocytes.

Leica Biosystems is pleased to announce that its flagship digital pathology system, Aperio GT 450 DX, has received 510(k) clearance from the US Food and Drug Administration.

Henry Schein, Inc. announced today that the Company will present at the following investor conferences in May.

Atea Pharmaceuticals, Inc. today announced the presentation of Phase 1 data highlighting the safety profile of bemnifosbuvir, an oral nucleotide polymerase inhibitor, at the European Society of Clinical Microbiology & Infectious Diseases Global 2024.

FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close.